Evolent Health
EVH
191 hedge funds and large institutions have $252M invested in Evolent Health in 2026 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 58 increasing their positions, 59 reducing their positions, and 61 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 59
9.03% less ownership
Funds ownership: 108% → 98.97% (-9%)
11% less funds holding
Funds holding: 215 → 191 (-24)
19% less call options, than puts
Call options by funds: $274K | Put options by funds: $337K
31% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 61
48% less capital invested
Capital invested by funds: $482M → $252M (-$230M)
Top Buyers
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$8.08M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.47M |
| 3 |
HF
HRT Financial
New York
|
+$3.27M |
| 4 |
VCM
Voleon Capital Management
Berkeley,
California
|
+$2.53M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$2.13M |
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$8.11M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$5.26M |
| 3 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$4.6M |
| 4 |
CHP
Castle Hook Partners
New York
|
-$3.75M |
| 5 |
Jane Street
New York
|
-$3.69M |
EVH Hedge Fund Activity: Q1 2026 in Review
191 of the 8,125 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q1 2026, worth a combined $252M — down 48% from $482M a quarter earlier.
Sellers outnumbered buyers: 61 funds closed out of EVH and 42 opened new positions — a net loss of 19 holders — while 59 trimmed existing stakes and 58 added.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $8.08M. The largest seller was JP Morgan Chase, cutting an estimated $8.11M.
- 191 institutional investors held Evolent Health (EVH) as of Q1 2026, down from 215 in Q4 2025.
- Funds reported $252M of Evolent Health stock for Q1 2026, down 48% quarter-over-quarter.
- 42 funds opened new Evolent Health positions in Q1 2026 and 61 closed out, a net change of -19 holders.
- The largest Evolent Health buyer in Q1 2026 was Eventide Asset Management, an estimated $8.08M added.
- The largest Evolent Health seller in Q1 2026 was JP Morgan Chase, an estimated $8.11M sold.
Based on aggregated 13F filings for Q1 2026.